全文获取类型
收费全文 | 4442篇 |
免费 | 379篇 |
国内免费 | 58篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 127篇 |
妇产科学 | 109篇 |
基础医学 | 386篇 |
口腔科学 | 99篇 |
临床医学 | 446篇 |
内科学 | 1028篇 |
皮肤病学 | 179篇 |
神经病学 | 170篇 |
特种医学 | 354篇 |
外科学 | 722篇 |
综合类 | 159篇 |
现状与发展 | 30篇 |
一般理论 | 1篇 |
预防医学 | 351篇 |
眼科学 | 63篇 |
药学 | 249篇 |
中国医学 | 11篇 |
肿瘤学 | 355篇 |
出版年
2024年 | 18篇 |
2023年 | 205篇 |
2022年 | 66篇 |
2021年 | 141篇 |
2020年 | 124篇 |
2019年 | 100篇 |
2018年 | 165篇 |
2017年 | 158篇 |
2016年 | 148篇 |
2015年 | 139篇 |
2014年 | 195篇 |
2013年 | 220篇 |
2012年 | 206篇 |
2011年 | 234篇 |
2010年 | 184篇 |
2009年 | 166篇 |
2008年 | 170篇 |
2007年 | 217篇 |
2006年 | 184篇 |
2005年 | 173篇 |
2004年 | 133篇 |
2003年 | 130篇 |
2002年 | 127篇 |
2001年 | 55篇 |
2000年 | 64篇 |
1999年 | 72篇 |
1998年 | 67篇 |
1997年 | 66篇 |
1996年 | 59篇 |
1995年 | 54篇 |
1994年 | 41篇 |
1993年 | 47篇 |
1992年 | 47篇 |
1991年 | 61篇 |
1990年 | 49篇 |
1989年 | 52篇 |
1988年 | 61篇 |
1987年 | 50篇 |
1986年 | 37篇 |
1985年 | 45篇 |
1984年 | 32篇 |
1983年 | 21篇 |
1982年 | 26篇 |
1981年 | 23篇 |
1980年 | 25篇 |
1979年 | 18篇 |
1978年 | 25篇 |
1976年 | 22篇 |
1975年 | 20篇 |
1974年 | 21篇 |
排序方式: 共有4879条查询结果,搜索用时 0 毫秒
61.
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression 总被引:18,自引:26,他引:18
Sullivan KM; Shulman HM; Storb R; Weiden PL; Witherspoon RP; McDonald GB; Schubert MM; Atkinson K; Thomas ED 《Blood》1981,57(2):267-276
Fifty-two of 175 (30%) survivors of allogeneic marrow transplantation developed chronic graft-versus-hose diseases (GVHD). Five with limited chronic GVHD had an indolent clinical course with involvement of only the skin and liver. Forty-seven with extensive chronic GVHD had an unfavorable multiorgan disorder that resembled several autoimmune diseases. Thirteen patients with extensive disease (group I) were not treated and only 2 survive with Karnofsky scores >- 70%. Mortality resulted from infections and morbidity from sica syndrome, pulmonary and hepatic insufficiency, scleroderma-like skin disease, and contractures. Another 13 (group II) received a median of 8 mo prednisone and/or a brief course of antithymocyte globulin, and 3 survive without disability. The other 21 (group III) were treated with a combination of prednisone (1.0 mg/kg/q.o.d.) and either cyclophosphamide, procarbazine, or azathioprine (all 1.5 mg/kg/day) for a median of 13 mo. Combination therapy was well tolerated with only modest myelotoxicity. Fifteen in group III had a good and 4 a fair response to treatment while 2 with no response died. Azathioprine and prednisone was the most effective regimen. All therapy has been discontinued in 12 group III patients: GVHD returned in 5 (including 2 who died in spite of retreatment) while 7 remain free of GVHD for a median of 11 (range 6-30) mo observation. Only I group III survivor is disabled and 16 of the original 21 are alive 2-4 yr after transplant with Karnofsky scores of 70%-100%. Thus, combination immmunosuppression appears to favorably affect and, in some cases, premanently arrest the adverse natural course of extensive chronic GVHD. 相似文献
62.
Incidence and determinants of moderate COPD (GOLD II) in male smokers aged 40–65 years: 5-year follow up 下载免费PDF全文
Roeland MM Geijer Alfred PE Sachs Theo JM Verheij Philippe L Salom Jan-Willem J Lammers Arno W Hoes 《The British journal of general practice》2006,56(530):656-661
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a major health problem with an estimated prevalence of 10-15% among smokers. The incidence of moderate COPD, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), is largely unknown. AIM: To determine the cumulative incidence of moderate COPD (forced expiratory volume in 1 second/forced vital capacity ratio [FEV1/FVC] <0.7 and FEV1 <80% predicted) and its association with patient characteristics in a cohort of male smokers. DESIGN: Prospective cohort study. SETTING: The city of IJsselstein, a small town in the Netherlands. METHOD: Smokers aged 40-65 years who were registered with local GPs, participated in a study to identify undetected COPD. Baseline measurements were taken in 1998 of 399 smokers with normal spirometry (n = 292) or mild COPD (FEV1/FVC <0.7 and FEV1 >or=80% predicted, n = 107) and follow-up measurements were conducted in 2003. RESULTS: After a mean follow-up of 5.2 years, 33 participants developed moderate COPD (GOLD II). This showed an estimated cumulative incidence of 8.3% (95% CI = 5.8 to 11.4) and a mean annual incidence of 1.6%. No participant developed severe airflow obstruction. The risk of developing moderate COPD in smokers with baseline mild COPD (GOLD I) was five times higher than in those with baseline normal spirometry (one in five versus one in 25). CONCLUSIONS: In a cohort of middle-aged male smokers, the estimated cumulative incidence of moderate COPD (GOLD II) over 5 years was relatively high (8.3%). Age, childhood smoking, cough, and one or more GP contacts for lower respiratory tract problems were independently associated with incident moderate COPD. 相似文献
63.
M Ye J Wysocki FR Gonzalez-Pacheco M Salem K Evora L Garcia-Halpin M Poglitsch M Schuster D Batlle 《Hypertension》2012,60(3):730-740
A newly produced murine recombinant angiotensin (Ang)-converting enzyme 2 (ACE2) was characterized in vivo and in vitro. The effects of available ACE2 inhibitors (MLN-4760 and 2 conformational variants of DX600, linear and cyclic) were also examined. When murine ACE2 was given to mice for 4 weeks, a marked increase in serum ACE2 activity was sustainable. In acute studies, mouse ACE2 (1 mg/kg) obliterated hypertension induced by Ang II infusion by rapidly decreasing plasma Ang II. These effects were blocked by MLN-4760 but not by either form of DX600. In vitro, conversion from Ang II to Ang-(1-7) by mouse ACE2 was blocked by MLN-4760 (10(-6) m) but not by either form of DX600 (10(-5) m). Quantitative analysis of multiple Ang peptides in plasma ex vivo revealed formation of Ang-(1-9) from Ang I by human but not by mouse ACE2. Both human and mouse ACE2 led to the dissipation of Ang II with formation of Ang (1-7). By contrast, mouse ACE2-driven Ang-(1-7) formation from Ang II was blocked by MLN-4760 but not by either linear or cyclic DX600. In conclusion, sustained elevations in serum ACE2 activity can be accomplished with murine ACE2 administration, thereby providing a strategy for ACE2 amplification in chronic studies using rodent models of hypertension and cardiovascular disease. Human but not mouse ACE2 degrades Ang I to form Ang-(1-9). There are also species differences regarding rodent and human ACE2 inhibition by known inhibitors such that MLN-4760 inhibits both human and mouse ACE2, whereas DX600 only blocks human ACE2 activity. 相似文献
64.
Diagnostic Accuracy of the Chinese Version of the Trail‐Making Test for Screening Cognitive Impairment 下载免费PDF全文
Ting Li MM Jingnian Ni MD Xuekai Zhang PhD Yumeng Li MD student Shenghua Kang MD student Fuyun Ma MD student Hengge Xie MD Bin Qin MD Dongsheng Fan MD Liping Zhang MD Yongyan Wang MD Jinzhou Tian MD PhD 《Journal of the American Geriatrics Society》2018,66(1):92-99
Background/Objectives
The Trail‐Making Test (TMT), which is commonly used to measure executive function, consists of two components (TMT‐A and TMTB). There is a lack of normative TMT data for Chinese elderly adults. This study aimed to evaluate the validity of the TMT in screening for cognitive impairment.Design
2,294 Chinese‐speaking adults aged 50 to 85: 1,026 with normal cognition (NC), 462 with mild cognitive impairment (MCI), 108 with Alzheimer's disease (AD), 113 with vascular mild cognitive impairment (VaMCI), 121 with vascular dementia (VaD), 282 with uncertain types of dementia, and 15 with mixed dementia. Receiver operating characteristic curve analysis was performed to test the ability of TMT scores to differentiate between NC and cognitive impairment.Results
Age, education, and sex were significantly associated with TMT completion time. The TMT‐A exhibited sensitivity of 77.8% and specificity of 92.0% with cut‐off value of 98.5 seconds for discriminating AD from NC. The TMT‐B had sensitivity of 83.3% and specificity of 91.8% with a cut‐off value of 188.5 seconds for discriminating AD from NC. The TMT‐A had sensitivity of 85.7% and specificity of 81.6% for discriminating NC from VaD with a cut‐off value of 77.5 seconds, and the TMT‐s had sensitivity of 81.6% and specificity of 83.9% with a cut‐off value of 147.5 seconds. The TMT had less sensitivity distinguishing MCI from NC.Conclusion
The Chinese version of the TMT is reliable for detecting AD or VaD but poor at distinguishing MCI from NC. 相似文献65.
Leila Mouelhi Leila Abbes Fatma Houissa Radhouane Debbeche Hayfa Mekki Majd Ben Rejeb Sinda Trabelsi Mohamed Salem Taoufik Najjar 《Journal of Crohn's and Colitis》2009,3(4):305-308
Inflammatory liver pseudotumor is a rare entity. Associations with several inflammatory conditions were reported but association with inflammatory bowel disease is unusual.We report the case of liver inflammatory pseudotumor occurring in the course of Crohn's disease in a 23-year-old woman and treated conservatively. 相似文献
66.
Gelan M. Salem Wafik M. El-Sheik Basma G. El-shanawany Khaled H. Afifi 《Neurosciences (Riyadh, Saudi Arabia)》2021,26(2):179
Objectives:To assess low dose altepase outcome and safety in comparison with a standard-dose regimen for acute ischemic stroke treatment in Egyptian patients.Materials:An observational prospective cohort non-randomized single blinded study was carried out during the period from November 2017 to December 2018. Eighty Egyptian acute ischemic stroke patients, all eligible for intravenous alteplase, were subdivided into 2 groups (40 patients in each group). Patients were thrombolysed at a dose of 0.6 mg/kg in the first group and 0.9 mg/kg in the second group. Both groups were compared in regard to safety and outcome. Safety was expressed by the rate of symptomatic intracranial hemorrhage (SICH) and 3 months mortality, while outcome was expressed by favorable outcomes at three months (modified Rankin Scale [mRS] of 0 to 2).Results:In the first group, 69.2% (n=27) achieved favorable outcomes at 90 days compared with 64.1% (n=25) in the second group (p=0.631). Ninety-day mortality was 5% (n=2) in the first group versus 2.5% (n=1) in the second group (p=0.556). Symptomatic intracranial hemorrhage was noted in 3 patients in the second group and zero patients in the first group (p=0.077).Conclusion:Low-dose alteplase could be a practical alternative for Egyptian populations with acute ischemic stroke especially in 3 to 4.5 hours window.Cerebrovascular stroke is the second death and the seventh disability leading cause worldwide.1 Tissue-type plasminogen activator (tPA) alteplase was the first medication approved by the Food and Drug Administration (FDA) for the acute ischemic stroke (AIS) treatment on June 1996, within 3 hours of stroke onset with a recommended dose of 0.9 mg/kg (maximum 90mg).2 In 2008, the safety of using alteplase within 3 to 4.5 hours of stroke onset was approved by the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Registry (SITS -ISTR)3 and the European Cooperative Acute Stroke Study (ECASS III).4 However, thrombolytic therapy use has not been widely adopted, especially in developing countries. The restricted time window (3 to 4.5 hours), intracerebral hemorrhage (ICH) risk and the drug high cost are major obstacles preventing its broad application.5 Coagulation and fibrinolysis responses differ among different races, which increase symptomatic intracerebral hemorrhage (SICH) risk with standard-dose alteplase6 in Asian populations, many Asian neurologists considered alteplase low dose to be a better alternative for ischemic stroke treatment. Many studies had been conducted in order to prove the efficacy and safety of Alteplase low dose.7-9 One of these studies was the Japan Alteplase Clinical Trial (J-ACT) conducted by Yamaguchi et al10 According to this study, using a 0.6 mg/kg dose of intravenous recombinant tissue plasminogen activator (rtPA) in Japanese patients was safe and effective. Despite the relatively stroke high rate among Egyptian populations, 963/100,000 inhabitants, only less than 1% of stroke patients receive intravenous thrombolysis. A major reason for this is the drug cost.11,12 Low-dose regimens (0.6 mg/kg) use will lower the economic burden of thrombolytic therapy in the community and will greatly promote the implementation of this therapy in Egypt. Our study aim was to assess the outcome and safety of alteplase low dose in comparison to the standard-dose regimen in AIS treatment in Egypt. 相似文献
67.
68.
69.
70.
ObjectivesTo evaluate the results and complications after combined use of Mathieu and incised plate technique for management of distal hypospadias in older children.Patients and methodsA total of 33 patients with primary distal penile hypospadias were operated upon using the Mathieu technique combined with deep urethral plate incision (Snodgrass technique). Each patient was evaluated according to the site of original urethral opening, original urethral stenosis, the presence and degree of chordee. The operative and postoperative results and complications were reported. Follow up of the patients was done weekly for 3 weeks postoperatively and then every month for at least 1 year.ResultsThe mean age was 6.5 ± 2.5 years (range 6–9 years). Bleeding was reported in one case. Wound infection was reported in two cases. Forcible slippage of stent occurred in one case. Meatal stenosis occurred in two cases and urethrocutaneous fistula occurred in one case. No urethral stenosis was reported in any of the patients.ConclusionCombined use of Mathieu and incised plate technique is suitable for primary distal hypospadias in older children with original meatal stenosis. 相似文献